Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › OKYO Leadership & Pay · Jul 22, 2026
On July 22, 2026, Chief Medical Officer Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of OKYO Pharma on… OKYO OKYO Pharma Ltd
On July 22, 2026, Chief Medical Officer Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of OKYO Pharma on NASDAQ at a price of $1.40 per share. OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.
More from OKYO Pharma Ltd OKYO Pharma CEO to present at Stifel Healthcare Conference Nov. 10-12 Nov 5, 2026 OKYO Pharma enrolls first patients in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain Oct 6, 2026 On July 28, 2026, Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma, purchased 3,363 ordinary shares on NASDAQ… Jul 28, 2026 OKYO Pharma Ltd announced its participation in the virtual BTIG Biotechnology Conference 2026 scheduled for July… Jul 27, 2026 Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on NASDAQ at $1.48 per share, increasing his… Jul 23, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
